The priming and activation of both CD4 and CD8 T cells have shown to be required for effective OX40-mediated tumor immunity, as depletion of these cells abrogated the regression of tumors [34]; therefore, we assessed both antigen-specific CD4 and CD8 T cells. This evidence concerns the gene TNFRSF4 and neoplasm.